## SEP 1 7 2003

## 3.0 Summary of Safety and Effectiveness Information

k032269 page 10f1

SPONSOR:

Synthes (USA) 1690 Russell Road Paoli, PA 19301 (610) 647-9700

Contact: Lisa M. Boyle

**DEVICE NAME:** 

Synthes (USA) 3.5 / 4.5mm LCP® Medial Proximal Tibia Plates

**CLASSIFICATION:** 

Class II, §888.3030 - Plate, Fixation, Bone

PREDICATE DEVICE:

Synthes (USA) Large Fragment LCP T- Plate

**DEVICE DESCRIPTION:** 

The Synthes (USA) 3.5 / 4.5 mm LCP® Medial Proximal Tibia Plates are contoured to match the anatomy of the medial proximal tibia with a limited contact low profile design. The plates are designed for either the right or left medial proximal tibia in a variety of shaft lengths. These plates will be available in both 3.5 mm and 4.5 mm versions. The plate head exhibits 2.0 mm holes for preliminary fixation with k-wires, or meniscal repair with

sutures.

**INTENDED USE:** 

The Synthes (USA) 3.5 / 4.5mm LCP® Medial Proximal Tibia Plates are intended to buttress metaphyseal fractures of the medial tibia plateau, split-type fractures of the medial tibia plateau, medial split fractures with associated depressions and split or depression fractures of the medial tibia plateau. Also, for use in the fixation of osteopenic bone and fixation of nonunions and malunions of the medial proximal tibia and tibia shaft.

SUBSTANTIAL EQUIVALENCE

Comparative information presented supports substantial equivalence.

MATERIAL:

Titanium and Stainless Steel

## DEPARTMENT OF HEALTH & HUMAN SERVICES



SFP 1 7 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms Lisa M Boyle Regulatory Affairs Associate Synthes (USA) 1690 Russell Road P.O. Box 1766 Paoli, PA 19301

Re: K032269

Trade/Device Name: Synthes (USA) 3.5 / 4.5mm LCP<sup>®</sup> Medial Proximal Tibia Plates

Regulation Number: 21 CFR 888.3030

Regulation Name: Single/multiple component metallic bone fixation appliances and

accessories

Regulatory Class: II Product Code: HRS Dated: July 22, 2003 Received: July 23, 2003

Dear Ms. Boyle:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

## 2.0 Indications for Use Statement

			Page	_1	of <u>1</u>
510(k) Number (if know	m): K032	269			
Device Name:	Synthes (USA) 3.5 / 4	.5mm LCP® Med	ial Proximal T	ibia Plates	
Indications/Contraindica	tions:				
The Synthes (USA) 3.5 / metaphyseal fractures of split fractures with association, for use in the fixation proximal tibia and tibia s	the medial tibia plateatiated depressions and sion of osteopenic bone	u, split-type fract split or depression	ures of the med n fractures of the	dial tibia pi he medial t	lateau, medial ibia plateau.
(PLEASE DO NOT WR	ITE BELOW THIS LII	NE - CONTINUE	ON ANOTHE	ER PAGE I	F NEEDED)
Co	oncurrence of CDRH, (	Office of Device	Evaluation (OI	DE)	
Prescription Use (Per 21 CFR 801.109)		OR (Division Sign Division of Ge and Neurologi	Off)  neral, Restor		-

Synthes (USA) 3.5 / 4.5 mm LCP® Medial Proximal Tibia Plates

Confidential